Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide in IFN-Refractory/Intolerant Chronic Phase CML
NCT00006091Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2000
- Primary completion
- Jan 2002
- Modality
- DNA Intercalators/Alkylators
01
Overview
A Phase 2 trial of arsenic trioxide in chronic myelogenous leukemia (CML), sponsored by University of Texas MD Anderson Cancer Center. Planned start Jun 2000; status: withdrawn.
02
Drugs
arsenic trioxide
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00006091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006091.